A treatment that targets immune cells’ primary adenosine receptor.
At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.
EOS-448 is a human immunoglobulin antibody that we are developing to inhibit the immunosuppressive activity of TIGIT, a cell receptor expressed on multiple immune cells, including CD8+ T cells, natural killer (NK) cells, and T regulatory cells (Tregs).
Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.
Latest press releases
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company…
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provide…
– Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L…